Jun 07, 2023 / 05:00PM GMT
Mike Yee - Jefferies - Analyst
I would love to get started here as we kick off from the lunch hour. We have the team from Morphic up here with us.
Morphic has obviously had an exciting year. We recently announced some very positive Phase 2 ulcerative colitis data, and the company is actively enrolling a Phase 2b randomized controlled study. And I would say that the IBD and ulcerative colitis space has definitely been of high attention, high focus this year, and there's a lot going on.
So I would just love maybe for Morphic or for Bruce, maybe you could make some opening comments about how you see Morphic and its oral alpha-4-beta-7 ulcerative colitis drug fitting into what seems to be an increasingly complex landscape in ulcerative colitis and make some comments about the profile of your drug and where you see this going?
Bruce Rogers - Morphic Holding, Inc. - President
Thanks. Sure, I can start out. I've got a little bit squeak in my voice today so Chris is going to kick in whenever I stop. I guess this is the key here. So yeah, MORF-057 has
Morphic Holding Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers